N@N

BioMedReports: Biotech Drug Company Preparing for Worst Case H1N1 Flu Scenario Using Extremely Promising New Technology (NYSE A

^{Published on 2009-07-31 04:14:16, Last Modified on 2009-07-31 04:14:27 - Market Wire}
 

LOS ANGELES, CA--(Marketwire - July 31, 2009) - BioMedReports, the news portal covering the biomedical news and financial sector, in a special report about the H1N1 flu pandemic, is reporting that CEL-SCI Corporation (NYSE Amex: [ CVM ]) is positioned to help combat the virus after diligently preparing for the worst case scenario with promising results.

CEL-SCI's preclinical studies have demonstrated that vaccines utilizing its proprietary L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology potentially induce protection against illnesses such as the swine influenza.

L.E.A.P.S. helps direct the immune response to the vaccine epitope and company scientists have been working to ensure that it will be available should the virus continue to spread and mutate.

"What this company's technology proposes is the ability to attack what comes out of the Swine Flu's mutations the moment it shows up, as opposed to what we have now," reports M.E. Garza of BioMedReports.

"The idea is very simple, if I'm looking for a bad guy and I know that bad guy is going to undergo facial reconstruction or hair color changes, the only way I'm going to be able to capture that bad guy is by focusing on parts of that person that cannot be changed," explains CEL-SCI's CEO Geert Kersten as he describes the dangerous influenza virus.

While some drug makers like Novartis AG, Sanofi-Aventis, Baxter, Novavax, Inc. and others are stockpiling vaccines and other treatments, government officials feel that may not be enough and it has been reported recently that there may even be a shortage of vaccines.

The alarming new special report titled "Who's Afraid of the Big Bad Flu" appears now at BioMedReports.com:

[ http://biomedreports.com/component/content/article/3544-whos-afraid-of-the-big-bad-flu-one-company-is-preparing-for-very-possible-worst-case- scenario.html ]

Biotech investors interested in accessing the complete database of clinical trials and upcoming FDA decisions can access that information on the same site:

[ http://biomedreports.com/fda-calendar/fda-calendar.html ]

About BioMedReports.com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features stock research reports, news, videos, stock commentaries, and more -- including FDA and Clinical Trial Calendars.

Disclosure: No positions